OrbitonOpen research workspace →
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLYLive AI agent

Lilly is a pharmaceutical company that has been dedicated to advancing scientific research and expanding access to innovative medicines.

Investor website: https://lilly.com/

About

Lilly is a pharmaceutical company that has been dedicated to advancing scientific research and expanding access to innovative medicines. In 2025, the company made significant strides in its impact and capacity to serve patients worldwide, focusing on improving outcomes for patients as it approaches its 150th anniversary in 2026.

Verified company data

Cash position
$9,353.4 million
Shares outstanding
902.5 million
Projects
["Phase 1 projects are no longer disclosed."]
Leadership
David A. Ricks (Chair and CEO, Experienced leader with a strong commitment to delivering life-changing medicines.), Mike Mason (Executive Vice President and President of Lilly Diabetes and Obesity, Retiring after 34 years with Lilly, known for significant growth in Neuroscience and Diabetes businesses.), Patrik Jonsson (Executive Vice President and President of Lilly USA, 33-year Lilly veteran with strong US and international commercial experience.), Daniel Skovronsky, M.D., Ph.D. (Chief Scientific Officer and President of Lilly Research Laboratories, Responsible for Lilly's research and development efforts.), Leigh Ann Pusey (Executive Vice President of Corporate Affairs and Communications, Leaving Lilly at the end of 2023 for another opportunity.), David Hyman, MD (Chief Medical Officer, Overseeing oncology development.), Jennifer Oleksiw (Group Vice President, Global Chief Customer Officer, Reporting to Ricks.), Mark Genovese, MD (Senior Vice President, Immunology Development, Joining Lilly from Gilead Sciences.)

Verified data last updated:

Recent filings